silence therapeutics ( aim : sln ) is a biotechnology company that develops gene therapeutic technology based on rna interference ( rnai ) .

they are involved in developmental research of targeted rnai therapeutics for the treatment of serious diseases .

formed in 1994 as a publicly traded drug research and development company , silence therapeutics has offices in london and berlin , with its corporate headquarters at 1 lyric square , london .

silence therapeutics

silence therapeutics strives to conduct its business in an ethical , responsible and transparent manner .
silence therapeutics plc’s iss governance qualityscore as of n / a is n / a .
silence therapeutics develops these structural modifications using three exclusive licences from the university of massachusetts .
arrowhead nets $ 9 . 6m investment from u . k . - based silence therapeutics
silence therapeutics daily update : silence ther . is listed in the pharmaceuticals & biotechnology sector of the london stock exchange with ticker
glassdoor gives you an inside look at what it ' s like to work at silence therapeutics , including salaries , reviews , office photos , and more . this is the silence therapeutics company profile . all content is posted anonymously by employees working at silence therapeutics .
silence therapeutics share price . sln - stock quote , charts , trade history , share chat , financials . silence ther . ord 5p
xconomy : arrowhead nets $ 9 . 6m investment from u . k . - based silence therapeutics
silence therapeutics website uses cookies . by continuing to browse you are agreeing to our use of cookies .
silence therapeutics is an aim listed biotechnology company focused on the discovery , delivery and development of novel rna therapeutics for the treatment of serious diseases with unmet medical need .
aim - quoted rna therapy specialist silence therapeutics plc ( lon : sln ) has bolstered its patent protections in the united states .
, chief scientific officer of silence , said :
these notifications from the uspto further strengthens silence ' s ip position in the arena of rnai therapeutics and builds upon the already strong proprietary technology silence offers its partners . the broad range of rnai therapeutics in terms of their possible length of base pairs again distinguishes silence from competitors which provide coverage for only very few lengths , if any .
silence therapeutics plc on thursday said it notes a press release from quark pharmaceuticals inc , reporting positive results from a phase 2 . . .
silence therapeutics is focused on the discovery , delivery and development of novel rna therapeutics for the treatment of serious diseases with unmet medical need . using its proprietary rna interference ( rnai ) technology and delivery systems , the company has a strategy of creating a new generation of therapeutics to help patients and grow shareholder value .
i applied through college or university . the process took 5 days . i interviewed at silence therapeutics ( berlin ( germany ) ) in january 2013 .
the targeting , delivery and on - going structural modification of sequences are the three platforms for silence therapeutics’s rnai therapeutic development . these three platforms are :
london , uk & nijmegen / utrecht , netherlands , september 12 , 2011 – silence therapeutics plc ( aim : sln ) ( “silence” ) , a leading global rna interference ( rnai ) therapeutics company , and interna technologies b . v . ( “interna” ) , a biopharmaceutical company developing pathway targeted microrna ( “mirna” ) - based therapeutics for cancer , today announce that they have entered into an agreement to develop novel microrna therapeutics for the treatment of cancer . this will combine the delivery capabilities of silence’s proprietary atuplex™ delivery system with interna’s novel micrornas .
silence therapeutics plc focuses on the discovery , development , and delivery of novel rna therapeutics . the company designs short interfering rna ( sirna ) molecules that trigger the rnai pathway and mediate the degradation of specific target messenger rnas . it is developing various candidates for the treatment of cancer , iron overload disorders , cardiovascular disease , alcohol use disorder , and other metabolic diseases . the company was formerly known as sr pharma plc and changed its name to silence therapeutics plc in may 2007 . silence therapeutics plc was incorporated in 1994 and is headquartered in london , the united kingdom .
silence therapeutics’ technology is protected by a valuable patent portfolio , which strengthens its competitive position within the industry and provides opportunities for licensing its technology to third - parties .
silence therapeutics has 781 number of twitter followers . the number of followers has grown 0 . 6 % month over month and grown 1 . 9 % quarter over quarter
silence therapeutics , a publicly traded biotech firm based in the u . k . , said it has made a $ 9 . 6 million equity investment in arrowhead pharmaceuticals .
rna therapeutics company silence therapeutics plc ( lse : sln ) named dmitry samarsky cso , effective sept . 14 . he was svp of technology and global business development at olix pharmaceuticals inc . ( seoul , south korea ) . vaccine company paxvax inc . ( redwood . . .
we have developed proprietary modifications to improve the robustness of rna sequences , together with advanced liposomal chemistries to enhance the delivery of therapeutics . this allows the development of therapeutics for diseases with high unmet clinical need . silence’s technology is currently in the clinic in a phase 2a pancreatic cancer trial .
the company ' s rnai therapeutic platform has received key validation through multiple partnerships with pharmaceutical companies including astrazeneca , dainippon sumitomo , pfizer / quark , and novartis / quark . silence is actively pursuing the establishment of additional partnerships . silence therapeutics has operations in both
silence therapeutics is a drug development company with a proprietary genetic medicine platform . silence operates in the maturing field or rna therapeutics , which harnesses the body’s natural mechanisms to create therapeutic effects within its cells . this technology can selectively silence or replenish the expression of any gene in the genome . we have developed proprietary modifications to improve the robustness of rna sequences , as well as advanced chemistries to enhance the effective delivery of therapeutic rna molecules to target cells .
forward - looking statements this press release includes forward - looking statements that are subject to risks , uncertainties and other factors . these risks and uncertainties could cause actual results to differ materially from those referred to in the forward - looking statements . all forward - looking statements are based on information currently available to silence therapeutics and silence therapeutics assumes no obligation to update any such forward - looking statements .
neuromuscular disease company sarepta therapeutics inc . ( nasdaq : srpt ) hired louise rodino - klapac as vp of gene therapy at its newly created gene therapy unit . she will continue to serve as acting cso at myonexus therapeutics inc . ( new . . .
the grant of us 9 , 695 , 423 is further confirmation by the us patent office of the validity of our patent claims that protect our innovative chemical modification technology , ” said ali mortazavi , silence therapeutics chief executive .
silence therapeutics’ rnai technology can selectively silence any gene in the genome , modulating gene expression down in a variety of organs and cell types , in vivo . the company has developed proprietary modifications to improve the robustness of rna sequences , as well as advanced chemistries to enhance the effective delivery of therapeutic rna molecules to target cells .
silence therapeutics plc ( aim : sln ) , a leading rna interference ( rnai ) therapeutics company , today announced that the us patent and trademark office ( uspto ) has issued a notice of allowance indicating that it will grant patents based on two applications : 12 / 986 , 389 and 13 / 230 , 084 . these cover respectively interfering rna molecules and lipid complexes used in drug delivery .
our mission is to use our technology to create a new generation of therapeutics which can improve outcomes for patients and , in the process , build shareholder value .
– potential for corporate activity . in our view , silence therapeutics’ current valuation should put the company on the radar of a number of potential suitors , whether they be in the rnai field already or looking to enter the sector by buying a valuable portfolio of rnai technology .
under the terms of the agreement , interna will provide silence with specific mirna sequences , which silence will formulate with its atuplex™ delivery system in order to develop multiple candidate drugs . silence and interna will undertake in vitro and in vivo studies of the candidate drugs developed under the agreement and select lead candidates for further evaluation . silence is eligible to receive upfront fees as well as staged research payments . further financial terms of the deal were not disclosed .
silence’s technology is clinical stage and is currently in active phase 2 and phase 3 trials carried out by a licensee .
silence said it believes that the granted patent claims are relevant to third party medicines that are in ongoing clinical trials .
silence therapeutics wants to put the kibosh on disease - causing genes . the company works in the field of rna interference ( rnai ) , a cutting - edge approach to treating disease that involves interfering with , or silencing , targeted genes associated with disease . its atuplex drug . . .
silence is currently conducting a phase i trial with atu027 in patients with advanced solid cancer . atu027 is based on silence´ proprietary atuplex™ delivery technology . interim data analysis from this trial were presented at the 2011 american society of clinical oncology conference and showed that atu027 is safe and well tolerated and provided broad support for atuplex™ as an effective sirna delivery technology with the potential to overcome the delivery challenges currently associated with rnai therapeutics .
supporting its ip portfolio , silence therapeutics has its own internally developed drug development programmes , along with a number of out - licenced programmes which use its technology . the company’s headline strategy is the development of its programmes , with highly stringent go / no - go criteria applied prior to making investment decisions .
the new us patent , ref 9 , 695 , 423 , provides further protection for silence ' s innovative chemical modification technology .
silence ther . has a 4 week average price of 134 . 50p and a 12 week average price of 130 . 50p .
the all - cash transaction could be a forerunner to discussions over a licensing deal or r & d collaboration , silence said . “we look forward to opening a constructive dialogue with arrowhead , ” ali mortazavi , silence’s ceo , said in a prepared statement .
interference ( rnai ) therapeutics for the treatment of serious diseases . rnai is a natural cellular process that occurs in almost all organisms and results in the silencing or shutting down of a target gene protein product . in an effort to combat a wide range of diseases , therapeutics that exploit the rnai process are being developed to halt the production of disease - causing proteins .
dr roel schaapveld , chief executive officer of interna technologies , said : “we are very excited about this collaboration with silence . working with atuplex™ and the experienced team at silence fits perfectly in our strategy to address the delivery challenge of rna based therapeutics upon systemic administration . atuplex™ may significantly contribute to the efficacy of several mirna drug candidates in our pipeline that have shown to reduce tumor growth in vivo and as such supports further development of these drug candidates towards the clinic . ”
the company has a history going back to january 1999 when atugen ag , a german biotechnology company focused on developing rnai therapeutics , was spun out of nasdaq listed ribozyme pharmaceuticals . in july 2005 atugen then completed the reverse takeover of aim listed sr pharma in conjunction with a £10 million fundraising and the business changed its name to silence therapeutics in may 2007 in order to reflect its increasing focus on rnai technology . the most recent capital raise was completed in may 2015 , with a gross £40 million being raised via a fundraising at 240p per share .
our technology harnesses the body’s natural mechanisms to create therapeutic effects within its own cells . this technology can selectively silence or replace any . . .
in april 2005 silence signed an option and licence agreement with quark pharmaceuticals giving quark access to the company’s aturnai® technology . there are currently four key programmes undergoing clinical trials which could create value for silence under the deal , in the near to medium - term , by generating milestone and royalty payments .
silence therapeutics plc ( lse : sln ) , london , u . k . business : cancer , pulmonary date announced : 2015 - 04 - 08 type : placing to be raised : up to l40 million ( $ 59 . 7 million ) shares : 16 . 7 million price : 240p shares outstanding prior : 52 . 1 million investor : institutional . . .
silence committed a sizable chunk of its cash reserves with the deal . the company said it had about $ 58 million in cash as of last june .
silence therapeutics plc ( lse : sln ) , london , u . k . business : cancer , renal , ophthalmic date announced : 2015 - 04 - 02 type : placing to be raised : up to l27 . 3 million ( $ 40 . 5 million ) shares : 11 . 4 million price : 240p shares outstanding prior : 52 . 1 million investor : . . .
thomas christély , chief operating officer of silence therapeutics , said : “we are pleased to be collaborating with interna , and it is in our interest to broaden the potential value of our atuplex™ delivery system as a vehicle to modify gene expression using different oligonucleotide classes , alongside our continuing focus on our internal sirna therapies . functional delivery into target cells is one of the greatest challenges facing most nucleic acid therapies . silence remains committed to the development of its atuplex™ and other delivery systems including dacc and dbtc as it seeks to overcome these challenges . ”
“as previously stated , we will consider potential licences under our patent estate , which could have a significant financial effect relative to the current market capitalisation of silence .
we will consider potential licences under our patent estate , which could have a significant financial effect relative to the current market capitalisation of silence .
says ceo ali mortazavi
silence had been evaluating several different rnai - focused companies and technologies since raising the equivalent of about $ 48 million from investors in 2015 , according to a news release .
silence therapeutics’ stake building comes in the midst of a difficult time for arrowhead in terms of its perception amongst investors and operational performance , the shares having fallen from just over 800 cents in august last year to their current levels of sub - 200 cents . this was primarily a result of arrowhead making the decision at the end of november to discontinue all three of its clinical programmes which utilised the firm’s proprietary delivery vehicle ex1 .
it is under this backdrop that silence decided in q2 2015 to increase investment in galnac - sirna conjugates for liver delivery . in april 2016 the company announced encouraging results from using an in - house structure , with potency observed believed to be competitive relative to peers . as a result , projects better suited to galnac will be transitioned to the technology , with liver therapeutics being a major focus for investment in the future . silence believes that its lipid nanoparticle delivery systems ( above ) are better suited to handling larger cargos , such mrna and for gene editing applications , with galnac best suited to rnai .
our technology is a highly specific and modular platform that enables us to inhibit or ‘silence’ the expression of disease - causing genes , allowing cells to revert to their healthy state .
the claims allowed on lipid complexes , the proprietary lipid which is a key element of silence ' s drug delivery technology atufect , cover any composition irrespective of the class of compound to be delivered and irrespective of the disease to be treated . the patent will both extend and widen silence ' s intellectual property ip related to the field of drug delivery .
david was appointed chief financial officer and company secretary of silence in july 2016 . david holds a b . a . in english & philosophy from birmingham university , and is a qualified chartered accountant . prior to joining silence , david’s relevant biotech experience includes several senior finance roles within both uk and us publicly owned life science companies , most recently as senior eumea finance director for biomarin pharmaceuticals inc . from 2010 to 2016 . prior to that he was cfo at plethora solutions plc ( 2008 - 2009 ) , and group financial controller at ark therapeutics from 2001 to 2008 , during which time ark undertook an ipo on the london stock exchange .
mortazavi told the financial news website proactive investors that silence intends to continue developing drugs on its own , rather than just buy other companies and have them perform the r & d work .
silence therapeutics plc is a united kingdom - based ribonucleic acid ( rna ) technology company . the company is primarily involved in the research and development of pharmaceutical products . the company ' s technology harnesses the body ' s natural mechanisms to create therapeutic effects within its own cells . the company has a has a genetic toolkit with its own therapeutic payloads to modulate gene expression up as well as down in preclinical in vivo models , and delivery systems for various organs and cell types .
silence therapeutics plc ( formerly sr pharma plc , formerly stanford rook holdings plc ) develops a new generation of medicines by harnessing the body ' s natural mechanism of rna interference , or rnai , within its cells . its proprietary technology can selectively inhibit any gene in the genome , specifically silencing the production of disease - causing proteins . using its enabling delivery systems , it has achieved an additional level of specificity by delivering our therapeutic rna molecules exclusively to target cells . silence ' s proprietary rna chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells , providing a powerful modular technology well suited to tackle life - threatening diseases .
we welcome the decision of the uspto on drug delivery as an appreciation of silence ' s contribution . drug delivery is key for the therapeutic use of functional nucleic acid molecules such as sirna and mirna . with this patent , silence is becoming an even more attractive partner for companies interested in the delivery of a variety of classes of compounds with sirna and mirna being only two of them .
another delivery method being worked on by silence is “galnac” , a highly efficient , simple and specific delivery approach whereby a sugar molecule ( n - acetylgalactosamine , galnac ) is conjugated to the sirna molecule .
there are currently 70 , 021 , 624 shares in issue and the average daily traded volume is 5 , 564 shares . the market capitalisation of silence ther . is £104 , 332 , 219 . 76 .
the claims allowed on interfering rna molecules cover any double - stranded ribonucleic acid molecule where o - alkyl modified nucleotides are alternating with unmodified or differently modified nucleotides on both strands having a length of 17 to fewer than 30 ribonucleotides . this kind of modified double - stranded ribonucleic acid molecules form a key component of silence ' s rnai therapeutics . the patent will extend silence ' s intellectual property related to double - stranded ribonucleic acid molecules to include molecules of 17 to fewer than 30 base pairs in length for use in methods for the treatment of disease . importantly , the patent will protect any such double - stranded ribonucleic acid molecule across all therapy areas and cover double - stranded ribonucleic acid molecules irrespective of the specific nucleotide sequence used .
silence’s investment comes following its may 2015 fundraise , subsequent to which the company has been looking at a number of rnai assets within both listed and unlisted companies . proving further value creating opportunities , silence has stated that the investment in arrowhead is a precursor to potential future deals which could include product licensing , r & d collaboration , technology sharing or a potential corporate transaction ( although no talks over a transaction are in progress at present ) .
if a gene sends out too many mrnas ( or “over - expresses” itself ) a cell can produce too much of a certain protein , potentially leading to diseases such as cancer , diabetes and many others . rnai is the method used to reduce the number of mrnas which get translated to these disease causing proteins . it minimises the over - expression of genes – effectively turning off , or silencing ( hence the name ) the disease causing genes . it is this area upon which silence therapeutics is focused , having developed proprietary rnai molecules and delivery systems .
president and chief executive officer of plaquetec limited . non - executive director of ardelyx inc , iox therapeutics limited , oncimmune holdings plc , thrombolytic science international , phesi llc and avrobio inc . chair of vium inc , cocoon biotech inc and cell medica limited . committee member of the u . s . food & drug administration science board .
silence is the only listed rnai player in europe and a pioneer in this technology . through the efforts of our skilled scientists over the years we have established a robust platform that allows us to effectively trigger rnai in specific cell types .
silence said it acquired about 8 . 4 percent of the outstanding shares of common stock in arrowhead ( nasdaq : arwr ) , which is based in pasadena , ca , but houses its research and development team in madison , wi .
the trial met its primary endpoint , with no safety issues being identified for the combination of atu027 with chemotherapy drug gemcitabine . silence now intends to progress atu027 through a suitable partnership rather than using its cash resources to fully develop it itself .
sr pharma , which rose out of stanford rook ltd . and has since changed its name to silence therapeutics , is a biotechnology company which was developing treatments derived from heat - killed mycobacterium vaccae ( nctc11659 ) and called srl172 or srp299 ( depending on the manufacturing process used ) in the 1990s . one of the founders of stanford rook , professor john stanford , helped dr charles akle to set up immodulon in 2007 . immodulon bought the rights to m . vaccae and is now continuing development under the name imm‑201 using an improved manufacturing process and target indications which are more relevant to its known mode of action .
silence therapeutics shares currently trade at 89p , capitalising the company at £62 . 1 million . with the last reported cash figure ( £47 . 59 million at as 30 th june 2016 ) being 8 months old , we estimate , based upon r & d and admin expenses being maintained at levels seen over the prior 18 months , and accounting for the transaction in arrowhead shares , that cash plus available for sale investments ( arwr ) currently stand at c . £43 million . thus , the markets are valuing the business , which incorporates the valuable intellectual property portfolio and programme of clinical trials , at just £19 . 1 million .
our technology harnesses the body’s natural mechanisms to create therapeutic effects within its own cells . this technology can selectively silence or replace any gene in the genome , modulating gene expression up as well as down in a variety of organs and cell types , in vivo .
arrowhead , for its part , emphasized that silence’s investment is the only official business the two firms have done together up to this point . “there have been no discussions about any potential transaction between the two companies , ” arrowhead said in a separate news release .
at silence we are developing novel rnai based therapies with the potential to transform patients’ lives . we use our proprietary technology platform to advance the next generation of genetic medicines , designed to intervene at the root of the problem by targeting the expression of disease - causing genes .
the company’s patented rnai chemistry is known as aturnai® , a proprietary technology with which individual sirna molecules are stabilised against degradation within the body . it is made up of highly potent , chemically stabilised sirna molecules which offer greater stability and better tolerability over conventional sirna molecules . aturnai® is one of the most thoroughly tested rnai therapeutics in humans and has an excellent safety record , with over 400 people dosed so far .
silence’s current enterprise value should prove to be no problem for larger pharma industry players to pay . in particular , we note that alnylam , largely considered to be the market leader in galnac technology , had cash & marketable securities of $ 1 . 04 billion as at 30 th september 2016 .
the delivery systems are subject to various patent families extending the scope of protection to the specific composition and use of the delivery systems . with the technologies able to deliver rna molecules to a wide variety of disease tissue silence has the opportunity to partner with other companies working in , or looking to enter , the rna field .
in interim results released last september the company revealed that in the previous six months it had obtained advice from three separate law firms indicating that multiple sirna based drugs currently in clinical development potentially fall within its issued claims . in reaction , silence has invited the relevant companies , which have remained un - named , to enter licensing negotiations .
settlement was recently reached over arbitration proceedings with quark over a milestone payment under the licensing deal in relation to qpi - 1002 . following the agreement silence will now receive a $ 1 million cash payment and is also eligible to receive either c . 2 % royalties plus milestones or 15 % of the clinical , regulatory and commercial milestone payments and royalties received by quark from partner novartis .
it has at least put the brakes on the share price . who knows - if there ' s any truth to the suggestions that alnylam might look to settle the patent dispute by taking over silence then now might be a good time to strike . certainly it seemed to me from the alnylam call that alnylam see the fitusiran death as tragic but by no means an end to their hopes for the drug .
arrowhead said on monday that it plans to continue development of several drug candidates , none of which are currently in clinical trials . the company is developing some candidates independently , but on others it is collaborating with partners , including amgen ( nasdaq : amgn ) , a large pharmaceuticals company based in thousand oaks , ca . in its release announcing the investment from silence , arrowhead said it will “continue to seek partnerships and collaborations that maximize the value of its assets . ”
delivering sirna into the body has long been a challenge for the rnai industry . in order to exert its effects , sirna must be safely and efficiently delivered into the target cells within the body , penetrate the cell membrane and survive for a sufficient amount of time once inside the cell . to address this challenge silence has developed a number of core proprietary liposomal delivery systems atuplex® , dacc , hepaplex and macplex , focused on delivering its specially modified aturnai® molecules to a variety of organs .
silence is the only listed rnai player in europe and a pioneer in this technology . through the efforts of our skilled scientists over the years we have established a robust platform that allows us to effectively trigger rnai in specific cell types . our inventions are protected by a broad intellectual property estate , which is a fundamental asset . together with our progress , the fact that the field is generally maturing means that rnai drugs are close to becoming a powerful genetic medicine modality at the disposal of doctors and patients .
dr . jenkins is a biopharma thought leader with 25 years of industry experience . until november 2017 , she was president and chief executive officer at leading gene therapy company , dimension therapeutics . prior to joining dimension in september 2014 , annalisa served as head of global research and development at merck serono pharmaceuticals from 2013 to 2014 , where she also served as executive vice president global development and medical from 2011 to 2013 . prior to this , dr . jenkins held several leadership roles at bristol myers - squibb from 1997 to 2011 , most recently serving as senior vice president and head of global medical affairs . earlier in her career , dr . jenkins was a medical officer in the british royal navy during the gulf conflict , achieving the rank of surgeon lieutenant commander .
in january 2009 quark announced the initiation of phase i / ii clinical trials for its drug candidate qpi - 1002 for the prevention of delayed graft function ( dgf ) in deceased donor adult kidney transplant patients . trials of the drug ( which are in partnership with novartis and incorporate silence’s aturnai® technology ) have progressed well , with phase iii trials in dgf , along with a phase ii study in acute kidney injury ( aki ) , currently ongoing . both trials are expected to have readouts in mid - 2018 , which provides a potential share price catalyst .
january this year saw silence use its cash resources to invest , on - market , in nasdaq listed arrowhead pharmaceuticals ( nasdaq : arwr ) . as at 13 th january a 9 . 21 % equity stake in arrowhead had been acquired , which will be held as an investment asset on the balance sheet . a total of $ 11 . 3 million was spent on the acquisition , equating to an average buying price of c . 165 cents per share . the shares currently trade at 212 cents , giving a gain on investment to date of c . 28 % .
dr . andrew j . richards is non - executive chairman at ixico plc , chairman at abcodia ltd . , chairman at cambridge temperature concepts ltd . , chairman at congenica ltd . , chairman at novacta biosystems ltd . , council member at biotechnology & biological sciences research council and a member at biological sciences research council . he is on the board of directors at silence therapeutics plc , cancer research technology ltd . , cambridge university hospitals nhs foundation trust , croggan ltd . , ieso digital health ltd . , arecor ltd . , babraham bioscience technologies ltd . and british science association . dr . richards was previously employed as independent non - executive director by summit corp . plc , independent non - executive director by vectura group plc , non - executive director by biowisdom ltd . , director - business development by chiroscience group plc , executive director by chiroscience ltd . , non - executive director by aitua ltd . , chairman by altacor ltd . , a principal by astrazeneca plc , a member by cancer research uk , executive director by celltech plc , chairman by ixico ltd . , non - executive director by pharmakodex ltd . , and non - executive director by theradeas ltd . he also served on the board at amedis pharmaceuticals ltd . , cambridge biotechnology ltd . , daniolabs ltd . , electra - net group ltd . and the bioindustry association . he received his doctorate degree from the university of cambridge .
– negative investor sentiment towards the rnai sector presents buying opportunity . as we have discussed above with arrowhead , companies involved in the rnai sector have seen a number of setbacks in recent months . share prices amongst rnai companies have plummeted , including a c . 70 % fall over the past 18 months for alnylam pharmaceuticals ( alny : nasdaq ) after the company announced the halting of several clinical trials . shares in dicerna pharmaceuticals ( drna : nasdaq ) , which is being sued by alnylam for “trade secret misappropriation” , are down by c . 90 % in just under two years and are currently trading at below cash . there is no negative read - across from any of these events to silence’s technology or activities in our view . thus , we believe that the present environment provides investors an opportunity to enter this highly prospective sector at a time when valuations are at the bottom of the cycle .
our management team is highly experienced in a variety of relevant sectors , from molecular biology and genetics to finance and investment banking .
our board of directors is formed by six accomplished members , two executive and four non - executive directors .
as the rna field evolves at an ever - faster rate , our tab helps us to assess its competitive position in technology and offers guidance in developing it in the most effective way .
we are committed to creating collaborations that maximise value for each of the partners .
effective sirna delivery to the right cells is a challenge given the complexity of the human body . discover how we address this .
find out more about our investment case , share price , corporate governance and related information . download our latest reports and announcements .
a summary of relevant information for our shareholders , investor faqs and key adviser details .
our upgraded , patient - friendly delivery technology is suitable for applications in a variety of disease settings . our liver centric pipeline is currently build around three main areas of high unmet need : haematology , metabolic and rare diseases .
we out - licensed our sirna stabilisation chemistry technology ( aturnai tm ) to quark pharmaceuticals , who have progressed drug candidates that use this technology to late clinical trials .
we have developed proprietary stabilising chemistries to improve the robustness of sirna sequences , together with advanced delivery systems that enable us to specifically target relevant cell types . this results in potent and highly specific drug candidates .
our inventions are protected by a broad intellectual property estate , which is a fundamental asset . together with our progress , the fact that the field is generally maturing means that rnai drugs are close to becoming a powerful genetic medicine modality at the disposal of doctors and patients .
we have out - licensed our sirna stabilisation chemistry technology ( aturnai tm ) to quark pharmaceuticals , who have progressed drug candidates that use this technology in late - stage clinical trials .
research in rnai has been progressing over the past 20 years , achieving nobel prize recognition in 2006 , and can now be seen to be transitioning from the experimental realm into the clinical . it is not often as an employee that you get a chance to be part of a nascent field like this that will make an impact on medicine .
we offer a vibrant culture and environment where innovation and creativity is encouraged . small , dynamic , with slick decision making and unencumbered by bureaucracy , we recognise contributions wherever they may be made within our team . our focus is on results , and opportunities for early career progression are here for team members who exceed their goals .
we should also mention we hope to have a lot of fun on the way , fully embracing the multi cultural mix of the talented professionals we employ .
our teams are located in west london , which is our corporate headquarters , and berlin where the majority of our research & development staff are based .
please review our current vacancies which are listed below . we are also interested to hear from candidates on a speculative basis either via the enquiries box or via e - mail to
our management team is highly experienced in a variety of relevant sectors , from molecular biology and genetics to finance and investment banking . this combination of skill sets enables the team to effectively execute our business plan .
our business model is designed to bring solutions to patients while generating shareholder value , by translating our proprietary technology into commercial drug products in a rapid and cost - effective way .
our corporate governance framework is based on using the leadership provided by our board to drive the effective execution of our strategy , ensuring that risk is appropriately mitigated and managed .
we have three board committees ( remuneration , audit and risk , and nominations ) , focused on providing the required oversight to maintaining the highest corporate governance standards . through these committees and regular interactions with the executive team , our board applies internal financial controls and approves the company’s policy and strategy .
the london stock exchange uses cookies to improve its website . the cookies for analytical purposes have already been set . for more details and how to manage cookies , please see our privacy and cookies policy .
as at 09 - jul - 2018 21 : 00 : 10 - all data delayed by at least 15 minutes .
* for instruments denominated in gbx , the trade value is shown in gbp when the traded currency is gbx or gbp . when the traded price is any other currency then the trade value is displayed in that currency .
* the company market capitalization reflects the london listed element of ordinary and preference shares only and is approximate . data provided by ftse russell .
the exchange accepts no responsibility for the content of the website you are now accessing or for any reliance placed by you or any person on the information contained on it .
by allowing this link the exchange does not intend in any country , directly or indirectly , to solicit business or offer any securities to any person .
the exchange accepts no responsibility for the content of the reports you are now accessing or for any reliance placed by you or any person on the information contained therein .
72 hammersmith road london w14 8th p : + 4420 . 34576900 f : + 447 . 957318494
reuters , the news and media division of thomson reuters , is the world’s largest international multimedia news provider reaching more than one billion people every day . reuters provides trusted business , financial , national , and international news to professionals via thomson reuters desktops , the world ' s media organizations , and directly to consumers at urltoken and via reuters tv . learn more about thomson reuters products :
all quotes delayed a minimum of 15 minutes . see here for a complete list of exchanges and delays .
immuno - oncology company apeiron biologics ag ( vienna , austria ) hired peter llewellyn - davies as cfo and cbo . he was cfo and cbo at medigene ag ( xetra : mdg1 ) . infectious disease company tetraphase pharmaceuticals inc . ( nasdaq : ttph ) named kamalam unninayar cfo . she . . .
neurological diseases play flex pharma inc . ( nasdaq : flks ) said christoph westphal will step down as ceo , effective july 3 . he will remain chairman . president of r & d william mcvicar will be interim ceo . cancer company viratherapeutics gmbh ( innsbruck , . . .
gruenenthal group ( aachen , germany ) named gabriel baertschi ceo , effective oct . 1 . he will replace eric - paul paques , who will retire . baertschi is country president for japan at astrazeneca plc ( lse : azn ; nyse : azn ) . cns play forum pharmaceuticals inc . . . .
final data from the phase iia portion of the open - label , german phase ib / iia atu027 - i - 02 trial in 23 patients with locally advanced or metastatic pancreatic adenocarcinoma showed that twice - weekly atu027 for 4 weeks plus once - weekly gemcitabine . . .
having addressed one of the two big problems of rnai delivery - getting therapeutic levels of the molecules inside cells - arrowhead research corp . now believes it has solved the second , with a modification to . . .
a post hoc analysis of the subgroup of 19 patients with metastatic pancreatic adenocarcinoma in the phase iia portion of the open - label , german phase ib / iia atu027 - i - 02 trial showed that twice - weekly atu027 for 4 weeks plus . . .
news corp is a network of leading companies in the worlds of diversified media , news , education , and information services .
real - time u . s . stock quotes reflect trades reported through nasdaq only .
international stock quotes are delayed as per exchange requirements . indexes may be real - time or delayed ; refer to time stamps on index quote pages for information on delay times .
quote data , except u . s . stocks , provided by six financial information .
data is provided
as is
for informational purposes only and is not intended for trading purposes . six financial information ( a ) does not make any express or implied warranties of any kind regarding the data , including , without limitation , any warranty of merchantability or fitness for a particular purpose or use ; and ( b ) shall not be liable for any errors , incompleteness , interruption or delay , action taken in reliance on any data , or for any damages resulting therefrom . data may be intentionally delayed pursuant to supplier requirements .
© thomson reuters . all rights reserved . any copying , republication or redistribution of lipper content , including by caching , framing or similar means , is expressly prohibited without the prior written consent of lipper . lipper shall not be liable for any errors or delays in the content , or for any actions taken in reliance thereon .
for inquiries related to this message please contact support . for sales inquiries , please visit urltoken
if you believe this to be in error , please confirm below that you are not a robot by clicking
i ' m not a robot
below .
please make sure your browser supports javascript and cookies and that you are not blocking them from loading . for more information you can review the terms of service and cookie policy .
dr . annalisa mary jenkins frcpc , mbbs , frcp , mrcp , f . r . c . p .
and compensation values are for the last fiscal year ending on that date . pay is salary , bonuses , etc . exercised is the value of options exercised during the fiscal year . currency in usd .
the pillar scores are audit : n / a ; board : n / a ; shareholder rights : n / a ; compensation : n / a .
scores indicate decile rank relative to index or region . a decile score of 1 indicates lower governance risk , while a 10 indicates higher governance risk .
arrowhead research is focused on developing , commercializing , and licensing a range of nanotechnology products and applications .
sign up for a free crunchbase account to follow and track organizations you care about .
terms of service | privacy policy | © 2018 crunchbase inc . all rights reserved .
descriptive keyword for an organization ( e . g . saas , android , cloud computing , medical device )
this field describes an organization ' s most recent funding status ( e . g . early stage venture , late stage venture , m & a )
last funding round type ( e . g . series a , seed , private equity )
transaction name : auto - generated name of transaction ( e . g . angel - uber )
transaction name : auto - generated name of transaction ( e . g . whatsapp acquired by facebook )
glassdoor will not work properly unless browser cookie support is enabled . learn how to enable cookies .
explore the many benefits of having a premium branded profile on glassdoor , like increased influence and advanced analytics .
changes won ' t be saved until you sign up for an enhanced profile subscription .
the cso at the time was a very good person and scientist that was always nice and make you feel comfortable . easy discussion with internal referral from university . easy question about lipids , sirna and oligonucleotide in general . german and english question . opportunity to come back after postdoc in the usa .
copyright © 2008–2018 , glassdoor , inc .
glassdoor
and logo are proprietary trademarks of glassdoor , inc .
the company highlighted that chemical modification technology is vital to prevent the degradation of therapeutic short interfering rna ( sirna ) molecules and to enable potent rna interference ( rnai ) , and as such it can have a substantial impact on the performance of rnai drugs .
the company is a publisher . you understand and agree that no content published on the site constitutes a recommendation that any particular security , portfolio of securities , transaction , or investment strategy is suitable or advisable for any specific person . you further understand that none of the information providers or their affiliates will advise you personally concerning the nature , potential , advisability , value or suitability of any particular security , portfolio of securities , transaction , investment strategy , or other matter .
you understand that the site may contain opinions from time to time with regard to securities mentioned in other products , including company related products , and that those opinions may be different from those obtained by using another product related to the company . you understand and agree that contributors may write about securities in which they or their firms have a position , and that they may trade such securities for their own account . in cases where the position is held at the time of publication and such position is known to the company , appropriate disclosure is made . however , you understand and agree that at the time of any transaction that you make , one or more contributors may have a position in the securities written about . you understand that price and other data is supplied by sources believed to be reliable , that the calculations herein are made using such data , and that neither such data nor such calculations are guaranteed by these sources , the company , the information providers or any other person or entity , and may not be complete or accurate .
from time to time , reference may be made in our marketing materials to prior articles and opinions we have published . these references may be selective , may reference only a portion of an article or recommendation , and are likely not to be current . as markets change continuously , previously published information and data may not be current and should not be relied upon .
proactive investors limited , trading as “proactiveinvestors united kingdom” , is authorised and regulated by the financial conduct authority . registered in england with company registration number 05639690 . group vat registration number 872070825 fca registration number 559082 . you can contact us here . market indices , commodities and regulatory news headlines copyright © morningstar . data delayed 15 minutes unless otherwise indicated . terms of use
described as being one of the most important recent discoveries in life sciences , rnai can selectively suppress disease causing genes . it has the potential to create a new class of therapeutic products for a broad range of diseases , many of which have an unmet need .
first discovered in the late 1990s , rna interference ( rnai ) is a highly prospective and rapidly advancing area of biotechnology concerned with gene suppression , or “gene silencing” – a process which enables the regulation of gene expression ( the process whereby information from a gene is used to produce proteins and rna ) . rnai is a naturally occurring process that occurs in organisms ranging from plants to mammals and can be utilised to selectively suppress the genes which cause certain diseases . this is done by preventing the over - expression of the gene and thus reducing the production of disease causing protein .
described as being one of the most important recent discoveries in life sciences , and one of the most exiting areas of drug discovery today , rnai technology has made significant leaps forward over the past decade , with the 2006 nobel prize in physiology or medicine being awarded to andrew fire and craig mello for , “their discovery of rna interference – gene silencing by double - stranded rna” .
having attracted the attention and investment of large pharma and other smaller specialist research companies , a number of rnai driven drugs are now moving to later stage clinical trials . however , the market remains at an early stage of development , with no rnai based drugs having been approved to date .
the nucleus of each living cell contains dna ( deoxyribonucleic acid ) , where specific genes and their genetic codes are stored . dna is the blueprint for the manufacture of proteins , the building blocks of life which enable the body to function . to pass on its instructions , dna itself does not leave the cell nucleus but instead creates a temporary copy of its genetic information . this copy is known as messenger rna ( mrna ) , an rna molecule which can leave the nucleus and transmits instructions to a cell’s ribosomes , the cell component responsible for synthesizing protein .
when rnai molecules are administered to patients they are absorbed into target cells . also known as short interfering rna ( sirna ) , these molecules in effect carry the “anti - code” to that of the mrnas which are being over - produced . once the sirnas bind to the mrnas the genetic code has been “interfered” with and can no longer be translated for protein production . as a result , protein production reduces , improving the diseased state .


peerless motor company was an american automobile manufacturer that produced the peerless brand of motorcars in cleveland , ohio , from 1900 to 1931 .

one of the " three ps " - packard , peerless , and pierce-arrow-the company was known for building high-quality , luxury automobiles .

peerless popularized a number of vehicle innovations that later became standard equipment , including drum brakes and the first enclosed-body production cars .

peerless motor company

peerless custom 8 was a car produced by peerless motor company . . . . more on wikipedia
peerless series 69 was a car produced by peerless motor company . . . . more on wikipedia
peerless series 67 was a car produced by peerless motor company . . . . more on wikipedia
peerless deluxe custom 8 was a car produced by peerless motor company . . . . more on wikipedia
peerless was an american automobile produced by the peerless motor company of cleveland , ohio . the company was known for building high - quality , precision luxury automobiles .
peerless motor car co . , cleveland , oh . peerless motor cars 1910 , 1909 , man driving car and woman sitting on porch .
national museum of american history library , nmah library , peerless cars , peerless motor car co . ,
peerless motor car co . , cleveland , oh . peerless motor cars 1910 , 1909 , tool box with receptacle for prest - o - lite tank and seat covers for peerless cars ( car driving in city ) .
the peerless motor car company began in 1869 as the peerless wringer and manufacturing company . it became the peerless manufacturing company in 1891 when it added bicycles to its line of wringer washing machines . the plant on lisbon street , adjacent to the cleveland and pittsburgh railroad tracks , had a rectangular , two - story office . the cleveland rubber company , whose general manager l . k . mcclymonds presided over the peerless manufacturing company , stood next door .
ford motor company , cleveland branch assembly plant , euclid avenue & east 116th street , cleveland , cuyahoga county , . . .
peerless motor car co . | encyclopedia of cleveland history | case western reserve university | case western reserve university
soon automobiles came along , and in 1902 , the company became peerless motor car co . at first , peerless manufactured racing cars , notably the green dragon driven by barney oldfield , but then went on to build luxury cars . the last car built on the assembly line by peerless motor car co . was in 1931 .
like many american automobile manufacturers , the great depression proved to be too much of a challenge to the peerless motor vehicle company . the company built its last cars in june 1931 , although some of these cars were sold as new models in 1932 .
in 1925 a new company peerless trading was set up in the uk to build british peerless trucks from spare parts and locally sourced components .
peerless was a united states automobile produced by the peerless motor car company of cleveland , ohio , usa . the company was known for building high - quality , precision luxury automobiles . peerless ' factory was located at 9400 quincy avenue in cleveland , ohio . [ 1 ] the company also built heavy trucks from 1911 to 1918 , with a large number being shipped to the uk during world war one .
established in 1869 in cincinnati to build clothes wringers , the peerless manufacturing company relocated to cleveland in the 1880s and began to build bicycles in 1891 , then switched to cars around the turn of the century . peerless soon found a pretty good niche in automobiles , building some of america’s most prestigious luxury cars , and found enough success at it to warrant changing the company name to peerless motor car company in 1905 .
this 1932 peerless , with a complete aluminum body and engine , was one of only 3 built by the peerless motor car co . crawford auto - aviation museum , wrhs .
along with pierce - arrow and packard , peerless was one of the “three ps” known for making cars . but peerless did not always manufacture cars . before the company was peerless motor car co . , it was known as peerless manufacturing co . their products included clothes wringers , bicycles , and eventually horseless single - cylinder * buggies called motorettes .
peerless roots dates back to 1874 in cincinnati , ohio as a manufacturer of clothes wringers , clothespins , and washboards . from the beginning , the peerless company was successful and within a short fifteen years , had outgrown their facilities and were searching for new space . the company formed with the mercantile manufacturing company in cleveland and the new organization became the peerless manufacturing company . the cleveland location offered several advantages over cincinnati , mainly better access to shipping .
the peerless motor car company remains something of an enigma in the cleveland automobile industry . while the peerless car ranked among the nation ' s most expensive , its production outlasted moat of cleveland ' s medium - priced automobiles . while the peerless factory
foreshadowed the best in modern architectural trends ,
the plant ' s manufacturing methods were twenty years behind the times when the company folded in 1931 .
and find catalogs by automobile manufacturers . let’s take a look at one of these catalogs , a catalog describing the 1910 car models for peerless motor car co .
historic american engineering record , creator , et al . peerless motor car company , east ninety - third street & quincy avenue , cleveland , cuyahoga county , oh . documentation compiled after . photograph . retrieved from the library of congress , < urltoken > .
in 1902 , the company reorganized as the peerless motor car company with a capitalization of $ 600 , 000 . the company maintained l . k . mcclyraonds as president and appointed lewis h . kittredge as its general manager and lewis d . mooers as its mechanical engineer . mooers
designed a range of cars which were very advanced for their time ,
with shaft drive , bevel gears , and pressed steel - frame construction .
the peerless motor car company produced 90 automobiles in 1902 , raising that total to 400 in 1903 . the company manufactured many of its own components , becoming one of the first cleveland automobile plants to achieve a degree of self - sufficiency . that self - sufficiency did not lower the cost of the company ' s automobiles . ranging in price from $ 2 , 800 to $ 11 , 000 , the peerless was , in 1903 ,
the most costly touring car built in america .
the peerless motor vehicle company was located in cleveland , ohio . the peerless company originally built clothes wringers and bicycles but in 1900 began producing its first automobiles . in its early years , peerless was known for its innovation in automobile design . it was the first american automobile manufacturer to mount the engine in the front , using it to power the rear wheels through a solid drive shaft . this design dominated the american automobile industry throughout most of the twentieth century .
peerless motor cars 1910 is located in the trade literature collection at the national museum of american history library . take a look at galaxy of images to see more pages from this catalog .
the peerless motor car co . , noted for its luxury automobiles , was established in cleveland in 1889 as the peerless wringer & mfg . co . , located on the city ' s east side at the junction of the cleveland & pittsburgh and the new york , chicago & st . louis railroads . by 1892 it had become the peerless mfg . co . originally a producer of washing - machine wringers , peerless moved to 2654 lisbon st . in 1895 and began making bicycles in the late 1890s . the company was manufacturing automobiles and parts in 1901 and was renamed the peerless motor car co . 2 years later . the company ' s factory , built in 1906 at 9400 quincy ave . , was designed by architect j . milton dyer .
in the early part of 1900 , the peerless manufacturing company became a parts supplier for the dedion - bouton matoretta , a french automobile manufactured in brooklyn , new york . when that company ceased production late in 1900 , peerless began manufacturing its own motorette automobile as well as offering general machining and brass foundry services .
in 1930 - 31 , peerless commissioned murphy body works of pasadena , california , to design what the company envisioned as its 1933 model . the task was assigned to a young frank hershey . hershey ' s design for peerless was a remarkably clean , elegant vehicle , powered by the company ' s planned v16 engine .
company director ron ham . it was set back to 2 litre form sometime in the 70’s or 80’s .
below is a list of all peerless cars & models that have come out so far . this peerless vehicle model list includes photos of peerless vehicles along with release dates and body types of each car . did you used to drive one of the old peerless cars on this list ? the company has had hits and misses , but definitely have put out some great cars . this poll features items like peerless series 67 and peerless custom 8 this list of car models made by peerless is a great way to see how peerless has evolved over the years . peerless types also have car class information available if you click on their names and go to their dedicated page .
historic american engineering record , creator , j milton dyer , john mcgeorge , j c schultz , ernest mcgeorge , and l k mcclymonds . peerless motor car company , east ninety - third street & quincy avenue , cleveland , cuyahoga county , oh . cleveland cuyahoga county ohio , 1968 . documentation compiled after . photograph . urltoken
whatever the rationale , peerless converted its factory at 9400 quincy avenue in cleveland from auto plant to beer brewery . hendry noted that peerless officially changed its name to the peerless corporation in 1934 , but just about every other source refers to post - automotive peerless as the brewing corporation of america , and we’ve found no reference to the peerless name being used afterward . carling’s black label beer proved its most popular product , and the company grew rapidly during the mid - 1950s , changing its name once again in 1954 to carling brewing company .
during the first world war , the company supplied trucks and military automobile chassis in support of the war effort .
the peerless manufacturing company of cleveland , ohio became the world leader in laundry equipment and continued to find new business in licensing its designs and name to manufacturers outside north america .
the body was designed and built by murphy body co . of california . while work was underway on a coupe body murphy received word from the peerless company to stop the project ; all automobile manufacturing was being ended . the sedan was driven back to cleveland and stored in the old peerless plant - which had been taken over by the carling brewing company .
to promote the company and its products , the company hired a famous race car driver , barry oldfield , to drive one of its cars . the car soon earned the nickname the
green dragon .
oldfield set a number of speed records in the green dragon , making peerless a respected name in automobile manufacturing . over time , a number of
green dragons
were built to advertise the company .
wonderful writing and photo , dan ! i found a peerless once with a 6 - digit patent number which proved to go back to 1869 . the company goes back to 1865 .
unfortunately , production was halted before the coupe versions could be completed . the decision was made to switch to beer production . the peerless sedan would be the final vehicle produced by the company .
the company survived for many years , struggling through the great depression era , and after completing one v - 16 prototype the company shut down in mid - 1932 . when the volstead act was repealed , ending prohibition , the peerless applied for a license to brew carling ' s black label beer and red cap ale . the company prospered and by the 1960 ' s had twenty - three breweries in the us . , canada , and overseas .
as with all peerless cars , this prototype is built largely of lightweight aluminum to a design by murphy . peerless was one of the very few companies to use a v - 16 engine , and the 465 - cubic - inch v - 16 in this prototype offered 173 bhp , enabling the car to cruise at speeds around 100 mph in great comfort . due to the economic climate at the time , the company decided that luxury cars were not the way to go . peerless ended car production entirely in 1932 , and redirected its efforts into the far more lucrative brewing business . as such , this car is the very last car produced by the pioneering peerless motor car company . the prototype was later purchased by the crawford auto - aviation museum .
by 1960 , peerless cars ltd . were in considerable financial difficulty and they were soon forced into liquidation . despite this , the enthusiasm of the directors continued , and rather than sell off the large quantities of spares and equipment for next to nothing , it was decided that they should form a new company and restart production on a more modest scale . the phase 2 peerless had ( in company press releases ) been describe
a sixty - horsepower four - cylinder peerless was created by mooers by 1904 . it was used by the company ' s new driver , eli ' barney ' oldfield for use in competition . the car was given the nickname , the ' peerless green dragon ' and would become a pillar in defining peerless ' s reputation for high performance coupled with quality and durability .
established in cleveland in 1900 , peerless motors began producing de dion ' machines ' under license from the french company . at the time , cleveland was the thriving center of automotive production in the united states . peerless employed barney oldfield as a driver of its green dragon racecar ; in early speed races peerless proved the durability of the product and setting world speed records .
soon , peerless began to promote its automobiles as luxury cars . the company ' s slogan became
all that the name implies .
advertising for the car described
an interior resembling a cozy and luxuriously furnished drawing room .
the focus on luxury meant that only wealthy americans could afford to own a peerless . unfortunately , although peerless had been known for its technical innovations in automotive design in the early years , it began to stagnate by the 1910s and 1920s . eventually , peerless no longer focused on the luxury market and began to manufacture automobiles for mainstream markets . the company changed its slogan to
now there ' s a peerless for everyone .
but let’s go back to 1910 when the company was busy making cars . peerless motor cars 1910 illustrates two models for that year . model 27 is a four - cylinder thirty horsepower car and model 28 is a six - cylinder fifty horsepower car . the catalog begins with a description of both models including improvements for the 1910 models . one improvement was “a larger gasoline tank , holding about 22 gallons . ”
established in cleveland in 1900 , peerless motors began producing de dion - bouton
machines
under license from the french company . at the time , cleveland was the thriving center of automotive production in the united states . peerless employed barney oldfield as a driver of its green dragon racecar ; in early speed races peerless proved the durability of the product and setting world speed records . peerless was noted for its use of flat - plane crankshafts in its engine designs .
carling itself remained in business afterward , merging with national brewing company in 1975 before being bought out by g . heileman brewing in 1979 . stroh then bought out g . heileman in 1996 and pabst in turn bought the carling brand from stroh in 1999 . pabst continues to market carling black label in the united states today , while carling products overseas continue to be marketed by the descendant company of the original canadian carling company .
my grandfather rh collins and his associates purchased peerless motor car company in may of 1922 . prior to that he was the president of cadillac . he left gm in 1922 along with his friend billy durant . he met durant in 1908 when he was general sales manager of john deere . he also was a general manager at buick and a vice president at gm exports sales prior to joining cadillac as president in 1918 . i think that he left peerless in about 1926 and retired in pasadens , ca . his son wilbur collins and son - in - law frank miller were on the board at peerless also . .
historic american engineering record , c . , dyer , j . m . , mcgeorge , j . , schultz , j . c . , mcgeorge , e . & mcclymonds , l . k . ( 1968 ) peerless motor car company , east ninety - third street & quincy avenue , cleveland , cuyahoga county , oh . cleveland cuyahoga county ohio , 1968 . documentation compiled after . [ photograph ] retrieved from the library of congress , urltoken
you can take todays peerless for a drive , you might get in trouble if caught .
peerless ' downfall was in its quality . [ citation ( source ) needed ] in the 1920s , the company was producing conservatively - styled vehicles that would last for ten or more years . current peerless owners held onto their cars , which ran very well ; new money buyers of luxury cars were attracted to lasalle , packard and the studebaker president series .
this article is about the american automobile . for other uses , see peerless ( disambiguation ) .
the peerless la type was a 7 - tonner of forward control layout fitted with a gardner engine .
two years after moving to cleveland , the company embarked on new business ventures ; bicycle building had become popular and peerless followed the boom , entering the business around 1891 . success again followed , but the business of bicycle making was short - lived , as auto production soon surpassed bicycles . peerless decided to follow the trend , and entered the new and uncharted world of automobile production .
the disagreement also resulted in peerless motors losing its franchise , which meant it eventually fell back into receivership . there had been an urgent need to find another project to keep the company afloat and john gordon managed to persuade jim keeble to join him as chief designer and ( the only ) engineer to help him develop a chassis for use with the corvette engine and gearbox . this car became know as the gordon gt . the new company ( the gordon automobile company ) approached many people in an endeavour to find strong financial backing without success and eventually , with only the prototype built , john gordon and jim keeble parted company . as it happens the project was resurrected at a later date and premises were established at eastleigh ( hampshire ) where ' gordon keeble ltd ' was founded . a total of 99 gordon keebles were built and many still survive to this day .
so it’s a bit of a fallacy to think that all automakers live and die by the car alone . as companies , they often have multiple streams of revenue and multiple paths to continued survival that frequently have nothing to do with cars . and sometimes , those non - automotive ventures keep the carmakers’ names – or even certain components , like engines – around long after auto production ceases , long after the official end dates given in the encyclopedias . no less , some of them make for good stories , as is the case with the peerless motor car company .
so in a way , you can still buy a peerless product . just don’t take it for a drive .
just as the car was ready to be shipped back to cleveland , the board of directors pulled peerless out of the automotive business and reoriented the company to brew beer under the carling black label brand . hershey ' s prototype was walled up in a room at the peerless factory where it sat until the end of world war ii . hershey ' s prototype is now owned by the crawford auto - aviation museum in cleveland .
peerless was the first company to successfully use a flyball governor to maintain speeds . they were the first to use a hinged steering wheel which allowed easier access into the cockpits for the driver . another first was the use of aluminum in their side - entrance tonneau along with being the first closed formal body in american production .
i have a lot of car pictures , including 2 of the 3 p’s packard & pierce arrow , but peerless has escaped me so far . metal recycling drives for war production were especially hard on peerless cars because of their high aluminum content .
of documentation regarding the factory . their documentation addresses the history of the structure and of the peerless operations in cleveland in detail .
around 1971 , i found 17 peerless automobiles sitting in sheds on a farm in illinois , along with about 200 packards . the peerless cars were very large and beautifully appointed on the inside . there used to be a saying : the three p’s , packard , peerless , pierce arrow . i visited that farm nearly 40 years later and most of the cars on that farm had rotted into the ground .
throughout the catalog are images of several peerless cars . one of these is the peerless limousine . “planned and built on attractive lines calculated to please the most refined tastes , ” the peerless limousine seated five people . passengers had the luxury of electric reading lights , armrests , and a speaking tube to communicate with the driver . other cars illustrated in the catalog include the touring car , roadster , and landaulet .
the following peerless vehicles are deemed
classic cars
by the classic car club of america ( ccca ) : 1925 series 67 ; 1926 — 1928 series 69 ; 1930 - 1 custom 8 and the 1932 deluxe custom 8 . however , all peerless vehicles are considered collectible .
peerless ' downfall was in its quality . in the 1920s , the company was producing conservatively styled vehicles that would last for ten or more years . current peerless owners held onto their cars , which ran very well ; new buyers of luxury cars were attracted to lasalle , packard and the studebaker president series . the great depression made it difficult for many to afford these high - priced vehicles . the small group of individuals who could afford one slowly diminished and the competition from other builders decreased the number of potential buyers .
were published in march / april 1961 by autosport , the motor and the autocar . although
the motor
considered that there was a little understeer or oversteer , with the handling remaining well balanced at all times , john bolster , writing for
autosport
, thought that the handling was not as sure as the peerless he had previously tested . he initially believed that the warwick had a tendency to bounce on bumpy corners , whereas his colleague in the passenger seat had been very impressed with the roadholding , so he discounted his first assessment . meanwhile , stuart bladon of
the motor
tested the same car and criticised the roadholding and suspension , suggesting that the combination of tr front suspension and the de dion rear end did not work , with the matching springs not being ideal . little roll was reported and although remaining stable and following the chosen line , he believed there was a tendency to understeer . for some unaccountable reason the car was at its best on right hand bends ! steering was noted to be heavier than the tr but redeemed itself at speed . lack of ground clearance and ineffectiveness of the handbrake were common complaints . the tr handbrake fitted to the peerless was excellent , however the warwick had an umbrella type pull handle located under the dashboard which lacked sufficient leverage .
a wonderful boost to sales followed and it was apparent that the available space at peerless motors was becoming insufficient to set up full production . fortunately a newly vacated factory became available on the farnham road ( slough ) , it was large shabby and neglected but ultimately cheap . peerless cars ltd was then set up with the production facilities while ' peerless motors ' continued to handle the sales . although not eligible for the 1958 london motor show , they were allocated a stand at earls court the following year . here they displayed a red model with steel wheels and a stripped lhd chassis with wire wheels . the display formed part of a select group of moulded plastic bodied vehicles which attracted much attention . the peerless was highly acclaimed by the press for is standard of finish and the simple layout of the de dion rear suspension , considered by some to be the most technically interesting feature of the show .
in 1931 peerless closed its business , unable to find a market for luxury cars during the depression . the business was reorganized and eventually became the
louis p . mooers had some experience in building automobiles , and he was tasked with leading the peerless company in this new direction . peerless licensed dedion bouton designs , building both four - wheeled motorettes and three - wheeled tricycles from the single cylinder dedion engines . mooers first design for peerless used a two - cylinder engine with a single - throw crankshaft in which both pistons moved in he same direction . the engine layout followed the panhard system design which had the engine in the front and drive taken through to transmission and on to the rear axle by a driveshaft . this two - cylinder vehicle was elegant , built of high quality , and suitable to traverse the continually evolving roadways .
the slough ( berkshire , england ) built peerless gt believe it or not , derives its name from the premises at which it was originally manufactured more than 50 years ago . these premises had long had the association with the peerless marque , though not for anything as exotic as 2 + 2 sports cars . the peerless works had derived its name from the world war 1 american army lorries that it once prepared for re - sale .
jim is correct in noting that the peerless prototype is in the crawford collection . the main gallery has just undergone a multi - million dollar renovation . the peerless is part of the fantastic “setting the world in motion” exhibit which highlights the cleveland area’s historic contribution to the transportation industry . definitely worth a visit .
in 1931 a new updated range was introduced as the peerless 90 series and heavy duty 12 - tonner model on a six wheel chassis with shaft drive .
a very unusual and technically advanced aspect of the design was the cambered rear axle which was positioned at a three - degree positive angle in each rear wheel and required a complete rear axle to cope . according to the peerless company , the benefit of this design was higher ground clearance for the differential and strong wood - spoke wheels . in modern terms , it would be similar in design to the ' positive offset rims . '
not withstanding all the criticism , even
the motor
considered that although the warwick may have seemed unacceptably rough , noisy and imperfect in some departments , at the basic price of £1666 it offered a distinctive combination of size , price and performance unique amongst british sportscars . at 105 mph , it was faster than any other closed four seater in it ' s price range .
following the armistice of 1918 , many lorries that had seen active service on the ' western front ' were brought back to a vehicle storage depot in slough ( berkshire england ) in order that they may be sold off as government surplus . a large majority of the lorries were american and a good proportion of these , were originally from the peerless lorry company in cleveland , ohio ( u . s . a . ) . sales continued well in to the roaring twenties but gradually what remained of the lorries required considerable re - conditioning . slough lorries and components ltd were set up to recondition these ex - wd ( war dept . ) lorries and as time progressed they began to incorporate more and more british material into them . eventually they were making most parts of the vehicles themselves and indeed the british firm outlasted the original american company ( as a lorry manufacturer ) by several years . as a point of interest , the american company transferred it ' s efforts to brewing alcoholic beverages !
throughout its history , peerless lagged behind in sales to cadillac and pierce - arrows , but it endured through many internal problems and management changes . in 1921 the company was sold to richard collins , the former president and general manager of cadillac . many of cadillac’s top level executives came with him . peerless assests were $ 14 , 000 , 000 . 00 and all looked well . sales soared where other companies were stumbling along . even with this success , troubles continued and collins and his team were out . this team would make the 1926 pontiac . the peerless continued in business with different models until 1931 , when it was decided that brewing a keg of carling black label beer would be more profitable . rh collins retired to pasadena , ca in about 1926 .
yet , peerless automobiles sold well . by 1906 , the company had outgrown its lisbon street facility . it purchased , as a site for a new plant , a former farm at the corner of quincy avenue and oakdale street ( e . 93rd street ) abutting the new york and st . louis railroad tracks . that same year , 1906 , lewis kittredge became president ; edwin parkhurst , vice - president ; and charles schmidt , chief engineer .
i have always respected peerless , and this car . it was designed by frank hershey , a renown walter m . murphy co . , coachbuilder ( pasadena ) designer . frank once told me that designing the peerless was his “proudest moment . ” i’ve seen it at the crawford museum ( cleveland ) and then drove by where the peerless plant “use” to be located . my understanding is that after the owner paid a huge amount for the car , that he didn’t keep it very long .
as the peerless evolved , it along with makes packard and pierce - arrow , became known as the ' three - p ' s ' of premium vehicles in the united states .
my grandmother was james bohannon’s personal secretary and she would often mention the ‘peerless 16 cylinder all aluminum’ . i think i saw that car at bohannon’s estate ‘greystone’ when she would visit him .
as the peerless evolved , it , along with makes packard and pierce - arrow , became known as the
three - ps of motordom
( premium vehicles ) in the united states .
interest generated from the paris motor show alone had suggested that the sales potential could be at least 1500 cars a year . one american distributor had asked for 80 a month , rising to 150 . the first three production peerless models came off the line toward the end of may 1958 and were displayed to the worldwide motoring correspondents early in june . press releases throughout the world acclaimed the peerless as the
sports car for the family man
. no longer was it a case of
either - or
for the young man who wanted a wife , a family and a sports car . another publicity stunt soon emerged as by far the most daring , in the form of an entry in the most demanding test of durability imaginable , le mans . what better publicity could there be than to enter the 1958 24 hour race ( please see the le mans page for the full story ) . they managed to get two entries , one confirmed and one reserve . the result of this race surpassed all expectation . after 24 hours of almost continuous rain , the peerless finished 16th , winning it ' s class .
unfortunately , at about this time trouble was brewing for the two peerless companies . it was proposed by another director that a further member , robert thornton , be brought onto the board . john gordon had reasons to disapprove of this move , but after a stormy meeting of the peerless cars directors , the entry of thornton was approved by a vote of three to two . john gordon and sam rostron promptly resigned . the resignation of this , the driving force behind the company caused some unease within the component supply companies and confidence was soon lost in the project . the last recorded factory built phase 2 peerless on record is chassis number gt2 / 00296 , although gt2 / 00294 was registered at a later date . so it would appear that only about 50 phase 2s were ever built . ( we do know that some were later assembled by various companies and registered following the demise of the even more short lived warwick project , built from spares left over but easily identified by their odd chassis numbers .
oldfield and mooers both left peerless in 1905 to join a st . louis business called moon . charles schmidt was given mooers position ; schmidt was the former chief engineer for packard and an experienced high speed driver .
in regard to the last line , back in my younger ( and stupider ) days i took many peerless products for a drive , and i grounded my kids for months when i caught them doing the same thing .
peerless was one of the first companies to use electric lighting . they used a gray & davis system as early as 1910 and then upgrading in 1913 to a single voltage gray & davis system which now included an electric starter .
howell , james w . and hershey , hershey franklin q . franklin q . hershey ' s murphy - bodied peerless v - 16 prototype collectible automobile , volume 12 , number 4 , december 1995 . pp . 56 - 63 .
that ’32 peerless prototype is indeed a gorgeous car . i can easily understand why , among all the terrific designs frank hershey created at murphy ( and of course elsewhere later ) , this was his “proudest moment . ” but in general i’m not very fond of peerless cars of the classic era . for some reason they usually had slab - flat sides , a look that ( to me ) suffered in comparison to the somewhat more rounded contours of the big packards and other contemporary classics .
with john gordon now firmly ' on board ' , a second alloy bodied four - seater prototype was built and exhibited at the 1957 paris motor show where it was subjected to close scrutiny by some of the standard triumph board . needless to say , words of encouragement were expressed . on returning to england , the car was driven to the triumph factory were lyndon mills , harry webster , martin tustin and alick dick ( of the triumph board of directors ) made the proper congratulatory remarks . the object of that visit was achieved , standard triumph agreed to supply all the components needed to start full production .
as much as we auto enthusiasts hyperfocus and sometimes glorify the carmakers that brought us our favorite four - wheeled finery , at the end of the day , they’re simply businesses doing what they can to make a buck . sure , car guys oftentimes took the helm and cranked out some magnificent machinery , but they wouldn’t do so unless somehow , some way , they were sure that what they were doing would benefit the company in the long run .
in the 1912 peerless catalog were the 415 cubic - inch engine rated at 38 horsepower , a 578 cubic - inch unit with nearly 50 horsepower available , and a massive 825 cubic - inch engine that produced an astonishing 60 horsepower . these horsepower figures were really about half of what the engine truly produced . peerless did not bother giving horsepower figures ; their patrons did not car for these details . the 825 cid engine still holds the guinness record as the largest engine ever cataloged and built for consumer use .
a good friend owns a 1931 peerless custom 8 club sedan that is under restoration . i have followed the progress on the car over the past several years and it is a magnificent looking machine with really excellent styling and attention to details such as curved door bottoms and splash pan that repeats that curve etc . there is a peerless club and they held a meet at the gilmore / ccca museum site this past summer . i hope one of the members writes in and lets us know how they can be contacted .
in 1930 a british 8 - tonner was introduced with a 4 - cylinder gardner diesel and optional pneumatic tyres based on a strengthened chassis of the earlier model . this was then followed by the peerless trader a new 8 - tonner with a meadows 6 - cylinder engine .
prior to it being displayed at the paris motor show , john bolster had tested the prototype for auto sport magazine , and the following year he carried out a more comprehensive test of a production car . the general finish had ( by then ) improved but some details needed more work . although heavier than the triumph and morgan two - seaters with the same power unit , the peerless was quicker off the mark . this was no doubt due to the de dion axle , which virtually eliminated wheelspin . also , the peerless accelerated better at the top end of the scale because of the more streamlined body which also gave the impressive top speed of 107 mph on test . the car ran straight and true at the high speeds it was capable of , and was surprisingly quiet when cruising in overdrive , but he felt that the engine could be heard and felt excessively at other times . the wheelbase in this new car was six inches longer and the track five inches wider that the equivalent triumph , giving a surprising improvement to the ride with virtually no roll , the de dion axle providing better wheel adhesion than the conventional rear end . this increase of track and wheelbase fulfilled the designer ' s intention of making this a comfortable four - seater coupe with the strength and reliability of the tr mechanical components .
peerless continued to promote their product through endurance challenges and racing . they faired rather well in the early glidden tours , with perfect scores achieved in 1906 - 1908 . they set a 1 , 000 - mile endurance record and the fastest time ever in the mt . washington hillclimb in new hampshire .
by the early 1910s the company was producing nearly every important component in their cleveland factory for their automobiles . in 1912 a new line of t - head six - cylinder models were introduced , each featuring seven main bearings and dual ignition . also in their engine line up was the tried - and - true four - cylinder t - head unit which was rated at about 25 horsepower . the companies products were durable , effective , and built to last . their methods employed advanced manufacturing processes and use of the finest materials available .
this vehicle was once in the possession of mr . barney pollard , a legendary collector who had a vast collection of exquisite cars . it was featured in the automobile quarterly article on peerless by maurice d . hendry in 1937 . it was restored sometime in the 1960s and again at a later point in history .
this example shown here represents a valiant attempt by james bohannon , the president of the company , to create a technically advanced vehicle with superb styling that could revitalize sales . the body is constructed of aluminum which was provided by alcoa . the engine is a massive 464 . 6 cubic - inch v - 16 engine capable of producing nearly 175 horsepower . peerless was one of the few marques to ever use a 16 - cylinder engine in one of their automobiles , and joined the ranks of cadillac and marmon . the coachwork was the result of the famous builder , murphy . the main designer on the project was the 22 - year old franklin hershey . the result was a four - door , five - passenger sedan sitting atop a 145 inch wheelbase . designs in other bodystyles , such as coupe , roadster , and convertible were also created giving bohannon a selection to chose .
in a little over 12 months since jimmy byrnes and bernie rodgers had first sought the opinion of john gordon , they managed to build a thriving company that was so overwhelmed by demand for their product , they could barely keep up . in fact production was lagging five weeks behind orders , which was mainly attributable to the meagre output of five cars a week . simon hill ( the sales manager ) is reported to have said that he never actually had to sell the cars , anyone that was interested got a quick ride up the road in the demonstrator ( if they were lucky ) , paid the deposit and mearly joined the growing waiting list . the fact that orders still came flooding in was made all the more astonishing when you discover that the list price of a peerless in 1958 was £990 + £500 purchase tax , yet a triumph tr3 could be bought for less than £1000 ( including tax ) .
precisely how many 2 and 3 . 5 litre warwicks were ever made is not known as records are simply not available , the normally accepted figure however is about 40 , although even that may be an exaggeration . if only to confuse matters even further , peerless and warwick registrations continued well into the 1960 ' s , made possibly by the liquidation sale of the remaining components after the closure of the factory . even up until june 1964 a magazine was advertising a
final consignment of new peerless phase 2 ' s at £895 - 0 - 0d ( including purchase tax ) prepared by lawrencetune of acton and sold by d . a . mullard ltd . , of middlesex .
the company started building tucks during 1911 fitted with their own 4 - cylinder gasoline engine in the 3 to 6 ton class . these early designs were of the bonnedted layout with a chain drive transmission . [ 2 ] in 1916 they launched a 2 - tonner with a shaft - drive . a large number were shipped to the uk following world war one to meet demand for trucks after large numbers were lost in france during the war and the military place orders with us supliers . when the war ended the military started to sell them off to the civilian market through distributor slough lorries and components ltd .
it’s kind of tragic to see a fine automaker discontinue cars and switch to something else , but in the 30s survival was everything and those willing to make radical changes were the ones that pulled through . of course we are plagued with a lot of what - ifs , in wondering what kind of car peerless would produce if it were still in business today .
this page uses some content from wikipedia . the original article was at peerless . the list of authors can be seen in the page history . as with tractor & construction plant wiki , the text of wikipedia is available under the creative commons by attribution license and / or gnu free documentation license . please check page history for when the original article was copied to wikia
for jimmy byrnes , it had been a natural choice to consider using triumph tr mechanical components , as more or less the entire management board of standard triumph were regular customers at his new restaurant , the saxon mill at warwick . in fact , lyndon mills ( one of the triumph board of directors ) was to become one of the strongest supporters of the peerless venture .
this vehicle , as with many other peerless automobiles , has cast aluminum body panels . it has the highly desirable electric starter and correct gary & davis electric headlights and sidelights . it is upholstered in maroon leather with a black cloth top and leatherette top boot . there are swivel - mounted jump seats in the rear which affords additional passenger room , bringing the total to seven .
the peerless model 36 - six , also known as the model k , was outfitted with the 578 cid engine and powered the elegant body which rested on a wheelbase that measured 137 - inches . the engine was inline with three pairs of cast - iron cylinders bolted to a large aluminum crankcase . it had a seven main bearing crankshaft made of imported steel and drove through a unique internally - expanding clutch to the four - speed transmission . the transmission was separately mounted to the frame . peerless used an open driveshaft and a separate arm between the transmission and the rear axle to help absorb the torque from the rear axle . the suspension was comprised of a live axle setup in both front and rear , with semi - elliptical leaf springs in the front and platform suspension in the rear .
the western development museum in saskatoon , saskatchewan , canada has a peerless model 36 right hand drive on display . it has only 100 miles on it . the wikipedia entry has a picture of it . apparently the family that ordered it never took possesion of it and it was parked until donated to the museum . it is displayed next to a pierce arrow . two beautiful limousines back to back from different eras .
james byrnes was an avid motor racing enthusiast who decided that he wanted a racing car built to his own specification . the car was to be for his own use on the racetrack , with a view to possibly supplying fellow club racers , if the project proved to be a success . with all this in mind , james byrnes ( known to many as jimmy ) approached bernie rodger ( an experienced racing engine tuner and
special
builder who was always referred to a bernie ) with a proposition to build such a car . mr rodger had an excellent pedigree , which not only included bodywork design and race engine tuning , but also the well acclaimed beart - rodger race car project ( francis beart being a meticulous norton expert ) . however , it wasn ' t long before the idea of a pure racing car had been set aside in favour of a more commercial venture . byrnes and rodger had decided that money could be made in the low volume production of a readily available low cost sports gt .
it may have also helped that cleveland was familiar ground for carling . founded in 1840 in london , ontario , carling’s first foray into the u . s . market came in 1880 when it bought out a cleveland brewery and sold carling beer either itself or through licensees in the united states until 1911 . and as hendry noted , peerless still had cash , facilities , and organizational capabilities ; it just needed a new product .
in 2008 , this model 36 peerless was brought to monterey , california where it was offered for sale by rm auctions as part of their ' sports & classics of monterey ' auction . it carried an estimated value of $ 600 , 000 - $ 700 , 000 and was offered without reserve . a high bid of just $ 368 , 500 including buyer ' s premium was enough to secure new ownership . the lot was sold .
owing to the increased speed of the new manufacturing process , it was expected that 25 bodies and thus 25 cars could be produced each week . meanwhile , the first two lhd phase 2 cars were shipped to the usa prior to john gordon visiting john posselius in detroit and dorothy dean in los angeles to promote the new model , on his return the future looked particularly bright . shortly afterwards a request was made by jim keeble , he wanted to know if peerless would sell him a chassis . his intention was to install a chevrolet corvette engine and gearbox for an enthusiastic customer of his , rick nielson . this was a remarkable coincidence , for at that moment john posselius ( of detroit ) was shipping two corvette engines to slough for a similar project . john gordon agreed , but only if the conversion was done in the peerless motors workshop . this was a wise move as someone else was thereby funding the necessary development work .